心脏疾病患者非心脏手术围术期评估决策新进展 

魏玥 赵集 计根林^通讯作者 

空军军医大学第一附属医院麻醉科，陕西省西安市新城区，71002； 

摘要：围术期心脏并发症是导致围术期死亡率增加的重要原因之一。在对病史了解、心脏功能状态的评级为基础 上对患者情况进行综合评估，以降低围术期相关风险及并发症为目的进行围手术期的优化管理。这篇综述的目的 是结合最新非心脏手术指南及临床试验结果为此类患者的围术期管理提供一定的参考。 

关键词：围术期管理；非心脏手术；风险评估

参考文献;

[1] Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, De Hert S, de Laval I, RM. 2022 ESC Guidelines on cardiovascular a ssessment and management of patients undergoin g non-cardiac surgery. Eur Heart J. 2022 Aug 2 6:ehac270. 

[2] Smilowitz NR, Gupta N, Ramakrishna H, Guo Y,Berger JS, Bangalore S. Perioperative major adverse cardiovascular and cerebrovascular eve nts associated with noncardiac surgery. JAMA C ardiol.2017;2(2):181-187. 

[3] Stubbs, D. J., Grimes, L. A. & Ercole, A. Performance of cardiopulmonary exercise testi ng for the prediction of post- operative compl ications in non cardiopulmonary surgery: a sys tematic review. PLoS ONE 15, e0226480 (2020) 

[4] Mol, K. et al. Preoperative coronary angio graphy in vascular surgery patients with asymp tomatic elevated high- sensitivity troponin T : a case series. Br. J. Anaesth. 123, 565–569 (2019). 

[5]Abuelkasem E, Wang DW, Omer MA, Abdelmoneim SS, Howard-Quijano K, Rakesh H, Subramaniam K. Perioperative clinical utility of myocardial deformation imaging: a narrative review. Br J Anaesth. 2019 Oct;123(4):408-420. 

[6]Smilowitz NR, Berger JS. Perioperative Card iovascular Risk Assessment and Management for Noncardiac Surgery: A Review. JAMA. 2020 Jul 2 1;324(3):279-290. 

[7]Hajibandeh S, Hajibandeh S. Effect of betablockers on perioperative outcomes in vascular and endovascular surgery: a sys-tematic revie w and meta-analysis. Br J Anaesth 2017;118(1): 11–21. 

[8]Lin Y, Ma L. Blood pressure lowering effect of calcium channel blockers on perio-perative hypertension. Medicine (Baltimore) 2018;97(4 8):e13152 

[9] Wang K, Wu M, Xu J, Wu C, Ma D. Effects of dexmedetomidine on perioperative stress, infl ammation, and immune function: systematic revi ew and meta-analysis. Br J Anaesth. 2019 Dec;1 23(6):777-794.

[10] Davy A, Fessler J, Fischler M, LE Guen M. Dexmedetomidine and general anesthesia: a nar rative literature review of its major indicati ons for use in adults undergoing non-cardiac s urgery. Minerva Anestesiol. 2017 Dec;83(12):12 94-1308.

[11]Gori, T . et al. Predictors of stent throm bosis and their implications for clinical prac tice. Nat. Rev. Cardiol. 16, 243–256 (2019) 

[12] Neumann, F . J. et al. 2018 ESC/EACTS gui delines on myocardial revascularization. Eur. Heart J. 40, 87–165 (2019) 

[13]Moon JY, Franchi F, DJ. Evolution of coron ary stent technology and implications for dura tion of dual antiplatelet therapy. Prog Cardio vasc Dis. 2018;60:478–490 

[14]Y eh, R. W. et al. Lesion complexity and o utcomes of extended dual antiplatelet therapy after percutaneous coronary intervention. J. A m. Coll. Cardiol. 70, 2213–2223 (2017) 

[15]Graham, M. M. et al. Aspirin in patients w ith previous percutaneous coronary interventio n undergoing noncardiac surgery. Ann. Intern. Med. 168, 237–244 (2018). 

[16]Tafur A, Douketis J. Perioperative managem ent of anticoagulant and antiplatelet therapy Heart 2018;104:1461–1467.